ELI LILLY & Co — Director's Dealing 2023

Feb 14, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ELI LILLY & Co (LLY)
CIK: 0000059478
Period of Report: 2023-02-10

Reporting Person: Mason Michael B (EVP & Pres., Lilly Diabetes)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-02-10	Common Stock	A	8023	$345.12	Acquired	39284	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-02-10	Restricted Stock Unit	$	A	3490	Acquired	2024-02-01	Common Stock (3490.0)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	957	Indirect

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock.